ICVS

ICVS

Malaria Becomes Harder to Treat Due to Multiple Mutations

Malaria is proving more difficult to treat than previously thought, as drug resistance is linked to multiple genetic mutations in the parasite rather than a single one. This is the conclusion of an international study involving scientists from ICVS published in Nature Communications.

ICVS Receives “Excellent” Rating in National FCT Evaluation

The Life and Health Sciences Research Institute (ICVS) has been awarded the highest classification of EXCELLENT in the most recent national evaluation of R&D Units, conducted by the Fundação para a Ciência e a Tecnologia (FCT) under the Multiannual Funding Programme for 2023/2024.

ICVS Researchers Join Innovative GALActIC Study to Combat IAPA

ICVS is a contributing partner in the launch of GALActIC, a pioneering European Union research project aimed at tackling Influenza-associated Pulmonary Aspergillosis (IAPA). The study, led by a European consortium, is funded by the European Partnership for Personalised Medicine (EP PerMed) and promises to pave the way for more effective identification and treatment of this severe condition.

Tiago Gil Oliveira Wins 2024 BIAL Clinical Medicine Award

ICVS researcher Tiago Gil Oliveira has been awarded the 2024 BIAL Clinical Medicine Award for his groundbreaking work in Alzheimer's disease research. His project, titled “Unveiling the Mysteries of the Brain’s Regional Susceptibility to Neurodegeneration in Alzheimer's Disease: From Neuropathology to Brain Magnetic Resonance Imaging,” identifies the specific regions of the brain most affected by Alzheimer's, offering hope for earlier diagnosis and more effective treatments.